10 Breast Cancer Clinical Trials in Fort Smith, AR (2026)

Q: How do I join a clinical trial in Fort Smith?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Fort Smith research site will contact you.

Recruiting Breast Cancer Studies in Fort Smith

NCT05879926Recruiting

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast ...

Fort Smith, ARPHASE33,960 participantsNRG Oncology

View Study Details

NCT06058377Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-I...

Fort Smith, ARPHASE33,680 participantsNational Cancer Institute (NCI)

View Study Details

NCT05929768Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast canc...

Fort Smith, ARPHASE32,400 participantsSWOG Cancer Research Network

View Study Details

NCT06418204Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or m...

Fort Smith, AR2,000 participantsWake Forest University Health Sciences

View Study Details

NCT06876714Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in...

Fort Smith, ARPHASE31,524 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT03723928Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread t...

Fort Smith, ARNA739 participantsSWOG Cancer Research Network

View Study Details

NCT06112613Recruiting

Mobile Health for Adherence in Breast Cancer Patients

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for ...

Fort Smith, ARNA410 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT06748222Recruiting

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led vers...

Fort Smith, ARPHASE3402 participantsNRG Oncology

View Study Details

NCT05108298Recruiting

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO....

Fort Smith, ARNA400 participantsEastern Cooperative Oncology Group

View Study Details

NCT05896189Recruiting

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors....

Fort Smith, ARNA386 participantsNRG Oncology

View Study Details

About Breast Cancer Clinical Trials in Fort Smith

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 10 breast cancer clinical trials recruiting participants in Fort Smith, AR. These studies are seeking a combined 15,901 participants. Research is being sponsored by NRG Oncology, National Cancer Institute (NCI), SWOG Cancer Research Network and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Fort Smith — FAQ

Are there breast cancer clinical trials in Fort Smith?

Yes, there are 10 breast cancer clinical trials currently recruiting in Fort Smith, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fort Smith?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fort Smith research site will contact you about next steps.

Are clinical trials in Fort Smith free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fort Smith studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 10 active trials in Fort Smith are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 22, 2026 from ClinicalTrials.gov